Comprehensive Genomic Profiling of Multiple Myeloma in the Course of Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations

• Published in: Blood 2015-12, Vol.126 (23), p.369-369
• Main Authors: Heuck, Christoph, Chavan, Shweta S., Stein, Caleb K., Tytarenko, Ruslana, Weinhold, Niels, Ali, Siraj, Miller, Vincent A., Thanendrarajan, Sharmilan, Schinke, Carolina, Mohan, Meera, Sawyer, Jeffery, Peterson, Erich Allen, Bauer, Michael, Ashby, Timothy C., Johann, Donald, van Rhee, Frits, Waheed, Sarah, Zangari, Maurizio, Davies, Faith E, Barlogie, Bart, Morgan, Gareth J
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V126.23.369.369

Introduction: Molecular assessment using conventional karyotyping, interphase FISH and gene expression profiling (GEP) has revealed multiple subgroups of myeloma with distinct pathogenesis and clinical course. While these technologies have tremendously impacted risk assessment they have had little contribution to the identification of therapeutic targets. Next generation sequencing (NGS) technology can identify mutations in genes of key cancer pathways, which impact outcome and are targetable by new drugs. Targeted gene panels can analyze clinical samples in sufficient depth affording the opportunity to incorporate NGS into clinical decision making in a meaningful way. Using the FoundationOne Heme test (F1H), we aimed to determine the mutational spectra of cancer-associated genes in multiple myeloma (MM), their association with disease risk and their effect on clinical outcome. Methods: DNA and RNA were extracted from CD138-selected MM cells. Comprehensive genomic profiling (CGP) using F1H was performed by Foundation Medicine, Inc (Cambridge, MA). Sequencing to an average depth of 470x (range: 5-3781) was performed on a HiSeq2500 sequencer. Sequences were analyzed for base substitutions, insertions, deletions, copy number alterations, and rearrangements in frequently altered genes. Annotated germline variants (dbSNP135) were removed. Somatic alterations in COSMIC (v62) and inactivating variants in tumor suppressor genes were called as biologically significant. GEP of CD138-selected MM cells using Affymetrix U133 2.0 plus arrays was performed as described. Overall survival analysis was done using log-rank tests. Results: CGP was performed on a total of 630 patients (3.4% MGUS, 6.5% SMM, 24.9% newly diagnosed MM, 24.9% relapsed MM, 18.8% MM in remission). We found increasing mutation load in from MGUS to relapsed MM. Later stages of the disease had an increased frequency of mutations in genes coding for epigenetic modulators and proteins involved in DNA repair. Alterations of TP53 and RB1 among others weresignificantly more frequent in GEP-defined high-risk (HR) disease and after relapse. Patients of the GEP-defined MF molecular subgroup carried a significantly greater mutation load. While there was no difference in the frequency of altered RAS/MAPK pathway genes between newly diagnosed and relapsed patients, we found an increased average mutant allele frequency in relapsed patients, indicating clonal selection. Using paired GEP data we identified gene expre